News

How Behavioral Economics Can Produce Better Health Care

How Behavioral Economics Can Produce Better Health Care

I’m a physician at the end of more than a decade of training. I’ve dissected cadavers in anatomy lab. I’ve pored over tomes on the physiology of disease. I’ve treated thousands of patients with ailments as varied as hemorrhoids and cancer.

And yet the way I care for patients often has less to do with the medical science I’ve spent my career absorbing than with habits, environmental cues and other subtle nudges that I think little about.

How Artificial Intelligence is Revolutionizing Healthcare

How Artificial Intelligence is Revolutionizing Healthcare

There’s currently a shortage of over seven million physicians, nurses and other health workers worldwide, and the gap is widening. Doctors are stretched thin — especially in underserved areas — to respond to the growing needs of the population.

Meanwhile, training physicians and health workers is historically an arduous process that requires years of education and experience.

Can Consumers Be Smart Health-Care Shoppers?

Can Consumers Be Smart Health-Care Shoppers?

Proponents of consumerism in health care say simple steps can save patients a lot of money. Skeptics say the system is too complex for shopping to pay off in most cases. Patients are told they need to take greater control over their care. But are laypeople capable of sifting through all their choices to make the right decisions—particularly when it comes to costs?

How U.S. Health Care Became Big Business

How U.S. Health Care Became Big Business

Health care is a trillion-dollar industry in America, but are we getting what we pay for? Dr. Elisabeth Rosenthal, a medical journalist who formerly worked as a medical doctor, warns that the existing system too often focuses on financial incentives over health or science.

How Flawed Science Is Undermining Good Medicine

How Flawed Science Is Undermining Good Medicine

A surprising medical finding caught the eye of NPR’s veteran science correspondent Richard Harris in 2014. A scientist from the drug company Amgen had reviewed the results of 53 studies that were originally thought to be highly promising — findings likely to lead to important new drugs. But when the Amgen scientist tried to replicate those promising results, in most cases he couldn’t.